This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Aventis Pharma Limited
Aventis Pharma Limited, a prominent player in the pharmaceutical industry, is headquartered in Great Britain and operates extensively across Europe and Asia. Founded in the early 2000s, the company has established itself as a leader in innovative healthcare solutions, focusing on prescription medicines and specialty pharmaceuticals. With a diverse portfolio that includes treatments for chronic diseases, oncology, and rare conditions, Aventis Pharma is recognised for its commitment to research and development. The company’s unique approach to drug formulation and patient care has positioned it as a trusted name in the market. Notable achievements include significant advancements in biopharmaceuticals and a strong emphasis on sustainability in its operations. Aventis Pharma Limited continues to strive for excellence, making a meaningful impact on global health.
DitchCarbon Score
How does Aventis Pharma Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aventis Pharma Limited's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aventis Pharma Limited, headquartered in Great Britain, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Sanofi, which influences its climate commitments and emissions reporting. As part of its corporate family relationship with Sanofi, Aventis Pharma Limited adheres to the climate initiatives and targets set by Sanofi, including those related to the Science Based Targets initiative (SBTi), CDP, and RE100. However, specific reduction targets or achievements for Aventis Pharma Limited are not detailed in the available data. While no absolute emissions figures are provided, the commitment to sustainability and climate action is evident through the cascading of initiatives from Sanofi. This includes a focus on reducing Scope 1, 2, and 3 emissions, although specific numbers and targets for Aventis Pharma Limited remain unspecified. In summary, while Aventis Pharma Limited does not present its own emissions data or reduction targets, it is aligned with the broader climate strategies of its parent company, Sanofi, reflecting a commitment to addressing climate change within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aventis Pharma Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
